Compositions and Methods for Stem Cell Expansion and Differentiation

• US 20070280989A1
• Filed: 09/21/2005
• Published: 12/06/2007
• Est. Priority Date: 09/21/2004
• Status: Abandoned Application

• Current Assignee: NVR Labs, Ltd.
• Original Assignee: NVR Labs, Ltd.
• Inventors: Shahar, Abraham, Nevo, Zvi, Rochkind, Shimon
• Application Number:
  US11/575,618
• Publication Number:
  US 20070280989A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61L 27/26 Mixtures of macromolecular compounds
• CPC Class Codes: A61L 27/3804 characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
• CPC Class Codes: A61L 27/3878 Nerve tissue, brain, spinal cord, nerves, dura mater
• CPC Class Codes: A61L 27/3895 using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
• CPC Class Codes: A61L 27/48 with macromolecular fillers
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: C08L 5/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
• CPC Class Codes: C08L 89/00 Compositions of proteins; Compositions of derivatives thereof foodstuff preparations A23J3/00
• CPC Class Codes: C12M 25/14 Scaffolds; Matrices in general C12N5/0068
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/235 Leukemia inhibitory factor [LIF]
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2531/00 Microcarriers
• CPC Class Codes: C12N 2533/52 Fibronectin; Laminin
• CPC Class Codes: C12N 2533/78 Cellulose
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/0607 Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696

Abstract

The present invention relates to compositions comprising stem cells and partially committed progenitor cells and to methods of controlling cell proliferation and differentiation, which can be used for expansion of stem cells and their subsequent differentiation. The present invention provides expanded population of essentially undifferentiated stem cells, which are useful in clinical procedures involving stem cell therapy, and a population derived thereof of which at least part of the cells are differentiated. The cells can be used per se, as a part of a cell-bearing composition comprising cross-linked hyaluronic acid-laminin gels or as a part of a composite implant for tissue regeneration.

Claims

1-73. -73. (canceled)

74. A composition for expanding stem cells, comprising a population of stem cells cultured in or on a biocompatible matrix comprising hyaluronic acid and laminin cross-linked to form a combined gel, further comprising nutrient culture medium, suitable for supporting the growth of stem cells wherein at least the majority of the cells are in their undifferentiated state.

75. The composition according to claim 74, wherein the composition is devoid of a feeder layer or conditioned medium.

76. The composition according to claim 74, wherein the stem cells are selected from stem cells of human origin and stem cells of non-human mammalian origin, and wherein the stem cells are selected from the group consisting of pluripotent embryonic stem cells, pluripotent adult stem cells, partially committed progenitor cells or combinations thereof.

77. The composition according to claim 76, wherein the partially committed progenitor cells are neural progenitor cells selected from spinal cord cells and nasal olfactory mucosa (NOM) cells.

78. The composition according to claim 74, wherein the nutrient culture medium is selected from a serum-free medium and a medium containing serum, wherein the serum is selected from the group consisting of autologous serum and non-autologous serum.

79. The composition according to claim 74, wherein the nutrient culture medium further comprises an agent supporting the growth of the cells in an undifferentiated state, selected from the group consisting of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), members of the interleukin 6 family (IL-6) and leukemia inhibitory factor (LIF).

80. The composition according to claim 74, wherein the population of stem cells cultured in or on said biocompatible matrix forms a monolayer or an embryoid body structure in the culture.

81. The composition according to claim 74, wherein the population of stem cells cultured in or on said biocompatible matrix substantially maintain their undifferentiated state throughout at least one duplication of the cell culture.

82. The composition according to claim 74, wherein the population of stem cells cultured in or on said biocompatible matrix are genetically modified.

83. A composition comprising a population of cells cultured in or on a biocompatible matrix comprising hyaluronic acid and laminin cross-linked to form a combined gel, further comprising nutrient culture medium, wherein the cell population is derived from stem cells, and wherein at least part of the cells are differentiated to a desired cell type.

84. The composition according to claim 83, wherein the composition is devoid of a feeder layer or conditioned medium.

85. The composition according to claim 83, wherein the cells are selected from cells of human origin and cells of non-human mammalian origin, and wherein the stem cells are selected from the group consisting of pluripotent embryonic stem cells, pluripotent adult stem cells, partially committed progenitor cells or combinations thereof.

86. The composition according to claim 85, wherein the partially committed progenitor cells are neural progenitor cells selected from spinal cord cells and nasal olfactory mucosa (NOM) cells.

87. The composition according to claim 83, wherein the differentiated cells are neural cells.

88. The composition according to claim 84, wherein the nutrient culture medium is selected from a serum-free medium and a medium containing serum, wherein the serum is selected from the group consisting of autologous serum and non-autologous serum.

89. The composition according to claim 83, wherein the nutrient culture medium further comprises an agent supporting the differentiation of the cells, selected from the group consisting of growth factors;

differentiation regulators selected from BDNF, retinoic acid, dopamine and NGF;

or combinations thereof.

90. The composition according to claim 83, further comprising synthetic or natural polymers in the form of a plurality of carriers dispersed within the combined gel.

91. The composition according to claim 90, wherein the carriers are positively charged microcarriers.

92. A composite implant comprising cells cultured in or on cross-linked hyaluronic acid-laminin gel further comprising nutrient culture medium and a biocompatible scaffold, wherein the scaffold supports the cultured cells.

93. The composite implant according to claim 92, wherein the cells are selected from undifferentiated stem cells, differentiated cells derived from the stem cells or combinations thereof.

94. The composite implant according to claim 93, wherein the stem cells are selected from pluripotent stem cells and partially committed progenitor cells.

95. The composite implant according to claim 94, wherein the partially committed progenitor cells are NOM cells.

96. The composite implant according to claim 93, wherein the differentiated cells are neural cells.

97. The composite implant according to claim 96, wherein the neural cells differentiated from partially committed NOM cells.

98. The composite implant according to claim 92 wherein the cells are selected from cells of human origin and cells of non-human mammalian origin.

99. The composite implant according to claim 92, wherein the scaffold encloses the cultured cells and the cross-linked hyaluronic acid-laminin gel.

100. The composite implant according to claim 99, wherein the scaffold is selected from tubular form further enclosing nanofibers and a grooved tubular form.

101. The composite implant according to claim 92, wherein the scaffold is positively charged.

102. The composite implant according to claim 92, wherein the scaffold comprises a cohesive biopolymer gel comprising a coprecipitate of at least one fibrillar protein and at least one sulfated polysaccharide.

103. The composite implant according to claim 102, wherein the cohesive biopolymer gel comprises of coprecipitate of dextran sulfate and gelatin.

104. The composite implant according to claim 103, wherein the scaffold is sutured without damage to the overall structure.

105. A method for expanding stem cells, comprising:

(a) providing a population of stem cells; and

(b) culturing the population of stem cells in or on a composition comprising biocompatible matrix comprising hyaluronic acid and laminin cross-linked to form a combined gel, further comprising nutrient culture medium, under conditions wherein the cultured cells are proliferating while maintaining their undifferentiated state.

106. The method according to claim 105, wherein the composition is devoid of a feeder layer or conditioned medium.

107. The method according to claim 105, wherein the population of the stem cells is obtained from a pre-culture grown on a feeder layer in a medium selected from a serum containing culture medium and a serum free culture medium.

108. The method according to claim 105, wherein the stem cells are selected from cells of human origin and cells of non-human mammalian origin, further wherein the stem cells are selected from the group consisting of pluripotent embryonic stem cells, pluripotent adult stem cells, partially committed progenitor cells or combinations thereof.

109. The method according to claim 105, wherein the nutrient culture medium further comprises serum.

110. The method according to claim 105, wherein the nutrient culture medium comprises an agent supporting the growth of the cells in an undifferentiated pluripotent state, selected from the group consisting of basic fibroblast growth factor (bFGF), epidermal Growth Factor (EGF), members of the interleukin 6 family (IL-6) and leukemia inhibitory factor (LIF).

111. The method according to claim 110, wherein the stem cells form a monolayer or an embryoid body structure in the culture.

112. The method according to claim 105, wherein the stem cells maintain their substantially undifferentiated state throughout at least one duplication of the cell culture.

113. The method according to claim 105, further comprising a step of transforming the population of the stem cell with a suitable vector comprising an exogene, wherein the vector is selected from the group consisting of a viral vector, a plasmid vector and a non-viral system.

114. The method according to claim 114, wherein transformation is performed prior to culturing the stem cell population in or on the hyaluronic acid and laminin combined gel or before re-seeding isolated cells during culture passages.

115. A method for differentiating stem cells, comprising:

(a) providing a population of stem cells; and

(b) culturing the population of stem cells in or on a composition comprising biocompatible matrix comprising hyaluronic acid and laminin cross-linked to form a combined gel, further comprising nutrient culture medium, under conditions wherein at least part of the stem cells differentiate to a desired cell type.

116. The method according to claim 115, wherein the composition is devoid of a feeder layer or conditioned medium.

117. The method according to claim 115, further comprising culturing the cells in a suspension comprising a plurality of microcarriers before culturing said cells in or on the hyaluronic acid and laminin combined gel.

118. The method according to claim 117, wherein the cells are cultured alternately as stationary cultures in or on the hyaluronic acid and laminin combined gel and subsequently in the solution comprising the plurality of microcarriers, wherein the final stage is the stationary culture in or on said hyaluronic acid and laminin combined gel.

119. The method according to claim 115, wherein the stem cells are selected from cells of human origin and cells of non-human mammalian origin, further wherein the stem cells are selected from the group consisting of pluripotent embryonic stem cells, pluripotent adult stem cells, partially committed progenitor cells or combinations thereof.

120. The method according to claim 115, wherein the composition further comprises serum free medium.

121. The method according to claim 115, wherein the culture medium comprises an agent supporting differentiation of the cells, selected from the group consisting of growth factors;

differentiation regulators selected from BDNF, retinoic acid, dopamin, and NGF;

or any combination thereof.

122. The method according to claim 115, wherein the cells form a monolayer in the culture.

123. A method for transplanting cells to an individual in need thereof, comprising transplanting a composite implant comprising the cells cultured in or on cross-linked hyaluronic acid-laminin gel, and a biocompatible scaffold, wherein the scaffold supports said cultured cell.

124. The method according to claim 123, wherein the cells are transplanted into an injured site of a spinal cord tissue.

125. The method according to claim 124, further comprising covering the site of the injured tissue with a thin biodegradable membrane.

126. The method according to claim 125, wherein the membrane comprises a coprecipitate of dextran sulfate and gelatin.

127. The method according to claim 125, wherein the membrane is attached to the injured site by interstitial sutures.

128. The method according to claim 123, wherein the cells are selected from undifferentiated stem cells, differentiated cells derived from the stem cells or combinations thereof.

129. The method according to claim 128, wherein the cells are selected from pluripotent stem cells and partially committed progenitor cells.

130. The method according to claim 129, wherein the partially committed progenitor cells are adult NOM cells.

131. The method according to claim 128, wherein the differentiated cells are neural cells.

132. The method according to claim 131, wherein the neural cells differentiated from partially committed NOM cells.

133. The method according to claim 123, wherein the scaffold comprises a cohesive biopolymer gel comprising a coprecipitate of at least one fibrillar protein and at least one sulfated polysaccharide.

134. The method according to claim 133, wherein the cohesive biopolymer gel comprises a coprecipitate of dextran sulfate and gelatin.